Sexually Transmitted Infections

Urologic Clinics of North America

Volumn 35, Issue 1, 2008, Pages 33-46

  Frenkl, Tara Lee ^a   Potts, Jeannette ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AZITHROMYCIN; BCG VACCINE; CEFIXIME; CEFTIZOXIME; CEFTRIAXONE; DICHLOROACETIC ACID; DOXYCYCLINE; ERYTHROMYCIN; ERYTHROMYCIN ETHYLSUCCINATE; FAMCICLOVIR; FLUOROURACIL; IMIQUIMOD; LEVOFLOXACIN; METRONIDAZOLE; OFLOXACIN; PENICILLIN G; PENICILLIN G DERIVATIVE; PODOPHYLLOTOXIN; PROBENECID; PROCAINE PENICILLIN; SPECTINOMYCIN; TETRACYCLINE; TINIDAZOLE; TRICHLOROACETIC ACID; VALACICLOVIR; WART VIRUS VACCINE;

CHLAMYDIASIS; GONORRHEA; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; INFECTION PREVENTION; LYMPHOGRANULOMA VENEREUM; NEISSERIA GONORRHOEAE; NEUROSYPHILIS; PRIORITY JOURNAL; REVIEW; SEXUALITY; SEXUALLY TRANSMITTED DISEASE; SINGLE DRUG DOSE; SYPHILIS; TREPONEMA PALLIDUM; TRICHOMONAS VAGINALIS; TRICHOMONIASIS; ULCUS MOLLE; URETHRITIS; UTERINE CERVICITIS; VIRUS INFECTION; WART VIRUS;

ANTI-INFECTIVE AGENTS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; MASS SCREENING; SEXUALLY TRANSMITTED DISEASES, BACTERIAL; SEXUALLY TRANSMITTED DISEASES, VIRAL; TREATMENT OUTCOME;

EID: 36448997745     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ucl.2007.09.003     Document Type: Review

References (64)

1. Aral S.O., Holmes K., Padian N.F., et al. Overview: individual and population approaches to the epidemiology and prevention of sexual transmitted diseases and human immunodeficiency virus infection. J Infect Dis 174 2 (1996) 127-133
2. Center for Disease Control and Prevention. Sexually transmitted disease surveillance 2005 (2006), US Department of Health and Human Services, CDC, Atlanta, GA. http://www.cdc.gov/nchstp/dstd/stats_trends/stats_and_trends.htm Accessed October 31, 2007
3. Weinstock H., Berman S., and Cates Jr. W. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health 36 1 (2004) 6-10
4. Centers for Disease Control and Prevention, Workowski K.A., and Berman S.M. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 55 RR-11 (2006) 1-94
5. Mawhorter S.D. Travel medicine for the primary care physician. Cleve Clin J Med 64 9 (1997) 483-492
6. Berg E., Benson D.M., Haraszkiewicz P., et al. High prevalence of sexually transmitted diseases in women with urinary infections. Acad Emerg Med 3 11 (1996) 1030-1034
7. Marrazzo J.M., Koutsky L.A., Stine K.L., et al. Genito human papilloma virus infection in women who have sex with women. J Infect Dis 178 6 (1998) 1604-1609
8. Perez G., Skurnick J.H., Denny T.N., et al. Herpes simplex type II and mycoplasma genitalium as risk factors for heterosexual HIV transmission: report from the heterosexual HIV transmission study. Int J Infect Dis 3 1 (1998) 5-11
9. Centers for Disease Control and Prevention. Expedited partner therapy in the management of sexually transmitted diseases (2006), US Department of Health and Human Services, Atlanta (GA)
10. DiCarlo R.P., and Martin D.H. The clinical diagnosis of genital ulcer disease in men. Clin Infect Dis 25 2 (1997) 292-298
11. Langenberg A.G., Corey L., Ashley R.I., et al. A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. N Engl J Med 341 (1999) 1432-1438
12. White C., and Wardropper A.G. Genital herpes simplex infection in women. Clin Dermatol 15 1 (1997) 81-91
13. Baker D.A. Diagnosis and treatment of viral STD's in women. Int J Fertil 42 2 (1997) 107-114
14. Margesson L.J. Vulvar disease pearls. Dermatol Clin 24 2 (2006) 144-155
15. Benedetti J., Corey L., and Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med 121 (1994) 847-854
16. Wald A., and Ashley-Morrow R. Serological testing for herpes simplex virus (HSV)-1 and HSV-2 infection. Clin Infect Dis 35 Suppl 2 (2002) S173-S182
17. Morrow R.A., Friedrich D., Krantz E., et al. Development and use of a type-specific antibody avidity test based on herpes simplex virus type 2 glycoprotein G. Sex Transm Dis 31 8 (2004) 508-515
18. Schmid G.P. Treatment of chancroid. Clin Infect Dis 28 Suppl 1 (1999) S14-S20
19. Hart G. Syphilis tests in diagnostic and therapeutic decision making. Ann Intern Med 104 (1986) 368-376
20. Golden M., Marra C., and Holmes K. Update on syphilis: resurgence of an old problem. JAMA 209 11 (2003) 1510-1515
21. Hicks C.B., Benson P.M., Lupton G.P., et al. Seronegative secondary syphilis in a patient infected with the human immunodeficiency virus with Kaposi Sarcoma: a diagnostic dilemma. Ann Intern Med 107 (1987) 492-495
22. Erbelding E.J., Vlahov D., Nelson K.E., et al. Syphilis serology in human immunodeficiency virus infection: evidence for false negative fluorescent treponemal testing. J Infect Dis 176 5 (1997) 1397-1400
23. Calonge N. Screening for syphilis infection: recommendation statement. U.S. Preventive Services Task Force. Ann Fam Med 2 (2004) 362-365
24. Greenblatt R.M., Lukehart S.A., Plummer F.A., et al. Genital ulceration as a risk factor for human immunodeficiency virus infection. AIDS 2 1 (1988) 47-50
25. Stamm W.E., Handsfield H.H., Rompalo A.M., et al. The association between genital ulcer disease and acquisition of HIV infection in homosexual men. JAMA 260 10 (1988) 1429-1433
26. Mabey D., and Peeling R.W. Lypmhogranuloma venerum. Sex Transm Infect 357 (2002) 1831-1836
27. Berger R.E., Alexander E.R., Harnisch J.P., et al. Etiology, manifestations and therapy of acute epididymitis: prospective study of 50 cases. J Urol 121 (1979) 750-754
28. Rees E. Treatment of pelvic inflammatory disease. Am J Obstet Gynecol 138 (1980) 1042-1047
29. Simms I., and Stephenson J.M. Pelvic inflammatory disease epidemiology: what do we know and what do we need to know?. Sex Transm Infect 76 (2000) 80-87
30. Scholes D., Stergachis A., Heidrich F.E., et al. Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. N Engl J Med 334 (1996) 1362-1366
31. Johnson R.E., Newhall W.J., Papp J.R., et al. Screening tests to detect Chlamydia trachomatis and Neisseria gonorrhoeae infections. MMWR Recomm Rep 51 RR-15 (2002) 1-38
32. Van der Pol B., Martin D.H., Schachter J., et al. Enhancing the specificity of the COBAS AMPLICOR CT/NG test for Neisseria gonorrhoeae by retesting specimens with equivocal results. J Clin Microbiol 39 (2001) 3092-3098
33. Centers for Disease Control and Prevention. Increases in fluoroquinolone-resistant Neisseria gonorrhoeae- Hawaii and California, 2001. MMWR Morb Mortal Wkly Rep 51 (2002) 1041-1044
34. Centers for Disease Control and Prevention. Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb Mortal Wkly Rep 56 14 (2007) 332-336
35. World Health Organization. Global incidence and prevalence of selected curable sexually transmitted infections: overview and estimates (2001), WHO, Geneva (IL)
36. Cotch M.F., Pastorek II J.G., Nugent R.P., et al. Trichomonas vaginalis associated with low birth weight and preterm delivery. The Vaginal Infections and Prematurity Study Group. Sex Transm Dis 24 6 (1997) 353-360
37. Sorvillo F., and Kerndt P. Trichomonas vaginalis and amplification of HIV-1 transmission. Lancet 351 9097 (1998) 213-214
38. Potts J.M., Ward A.M., and Rackley R.R. Association of chronic urinary symptoms in women and ureaplasma urealyticum. Urology 55 4 (1999) 486-489
39. Taylor-Robinson D., and Furr P.M. Update on sexually transmitted mycoplasmas. Lancet 351 3 (1998) 12-15
40. Colli E., Landoni M., and Parazzini F. Treatment of male partners and recurrence of bacterial vaginosis: a randomised trial. Genitourin Med 3 4 (1997) 267-270
41. Hanson J.M., McGregor J.A., Hillier S.L., et al. Metronidazole for bacterial vaginosis. A comparison of vaginal gel vs. oral therapy. J Reprod Med 45 11 (2000) 889-896
42. Ho G.Y.F., Bierman R., Beardsley L., et al. Natural history of cervicovaginal papilloma virus infection in young women. N Engl J Med 338 (1998) 423-428
43. Frydenberg M., and Malek R.S. Human papilloma virus infection and its relationship to carcinoma of the penis. Urologe A 7 (1993) 185-198
44. Syrjanen K.J., Heinonen U.M., and Kauraniemi T. Cytologic evidence of the association of condylomatous lesions with dysplastic and neoplastic changes in the uterine cervix. Acta Cytol 25 (1981) 17-22
45. Adam E., Berkova Z.D., Axnerova Z., et al. Papillomavirus detection: demographic and behavioral characteristics influencing the identification of cervical disease. Am J Obstet Gynecol 182 (2000) 257-264
46. Kulasingham S.L., Hughes J.P., Kiviat N.B., et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA 288 (2002) 1749-1757
47. Walboomers J.M., Jacobs M.V., Manos M.M., et al. Human papilloma virus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189 (1999) 12-19
48. Frisch M., Glimelius B., van deen Brule A.J., et al. Sexually transmitted infection as a cause of anal cancer. N Engl J Med 337 19 (1997) 1350-1358
49. Schneider A., Kirchmayr R., DeVilliers E.M., et al. Subclinical human papillomavirus infection in male sexual partners of female carriers. J Urol 140 (1988) 1431-1434
50. Campion M.J., Singer A., Clarkson P.K., et al. Increased risk of cervical neoplasia in consorts of men with penile condylomata acuminata. Lancet 1 (1985) 943-946
51. Arican O., Suneri F., Bilgie K., et al. Topical imiquimod 5% cream in external genital warts: a randomized, double-blind, placebo-controlled study. J Dermatol 31 8 (2004) 627-631
52. Langley P.C., Tyring S.K., and Smith M.H. The cost effectiveness of patient applied versus provider administered intervention strategies for the treatment of external genital warts. Am J Manag Care 5 (1999) 69-77
53. Perry C.M., and Lab H.M. Topical imiquod: a review of its use in genital warts. Drugs 58 (1999) 375-390
54. Wiley D.J., Doughlas J., Beutner K., et al. External genital warts: diagnosis, treatment and prevention. Clin Infect Dis 35 (2002) S210-S224
55. Cardamakis E., Kotoulas I.G., Metalinos K., et al. Treatment of urethral condylamata acuminate or flat condylomata with interferon. J Urol 152 (1994) 2011-2013
56. Metawea B., El-Nashar A.R., Kamel I., et al. Application of viable Bacille Calmette-Guerin topically as a potential therapeutic modality in condylomata acuminate: a placebo controlled study. Urology 65 20 (2005) 247-250
57. Markowitz L.E., Dunne E.F., Saraiya M., et al. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 56 RR-2 (2007) 1-24
58. Joura E.A., Leodolter S., Hernandez-Avila M., et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 369 9574 (2007) 1693-1702
59. Garland S.M., Hernandez-Avila M., Wheeler C.M., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356 (2007) 1928-1943
60. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356 (2007) 1915-1927
61. Villa L.L., Costa R.L.R., Petta C.A., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6 5 (2005) 271-278
62. Harper D.M., Franco E.L., Wheeler C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 (2006) 1247-1255
63. Villa L.L., Costa R.L.R., Petta C.A., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95 11 (2006) 1459-1466
64. Saslow D., Castle P.E., Cox J.T., et al. American Cancer Society guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 57 (2007) 7-28